Merck's New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.

Merck's two-drug HIV regimen matched Gilead's blockbuster Biktarvy in Phase 3 trials and is under FDA review as the company prepares for Keytruda's patent cliff. ...